{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:31:02Z","timestamp":1791412262212,"version":"4.3.3"},"reference-count":69,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Immunotherapeutic herpes simplex virus 2 (HSV-2) vaccine efficacy depends upon the promotion of antigen-specific immune responses that inhibit reactivation or reactivated virus, thus controlling both recurrent lesions and viral shedding. In the present study, a candidate subunit vaccine, GEN-003\/MM-2, was evaluated for its ability to induce a broad-spectrum immune response in mice and therapeutic efficacy in HSV-2-infected guinea pigs. GEN-003 is comprised of HSV-2 glycoprotein D2 (gD2\u0394TMR\n            <jats:sub>340-363<\/jats:sub>\n            ) and a truncated form of infected cell polypeptide 4 (ICP4\n            <jats:sub>383-766<\/jats:sub>\n            ), formulated with Matrix M-2 (MM-2) adjuvant (GEN-003\/MM-2). In addition to eliciting humoral immune responses, CD4\n            <jats:sup>+<\/jats:sup>\n            and CD8\n            <jats:sup>+<\/jats:sup>\n            T cells characterized by the secretion of multiple cytokines and cytolytic antigen-specific T cell responses that were able to be recalled at least 44 days after the last immunization were induced in immunized mice. Furthermore, vaccination with either GEN-003 or GEN-003\/MM-2 led to significant reductions in both the prevalence and severity of lesions in HSV-2-infected guinea pigs compared to those of phosphate-buffered saline (PBS) control-vaccinated animals. While vaccination with MM-2 adjuvant alone decreased recurrent disease symptoms compared to the PBS control group, the difference was not statistically significant. Importantly, the frequency of recurrent viral shedding was considerably reduced in GEN-003\/MM-2-vaccinated animals but not in GEN-003- or MM-2-vaccinated animals. These findings suggest a possible role for immunotherapeutic GEN-003\/MM-2 vaccination as a viable alternative to chronic antiviral drugs in the treatment and control of genital herpes disease.\n          <\/jats:p>","DOI":"10.1128\/jvi.02745-12","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T05:06:58Z","timestamp":1359608818000},"page":"3930-3942","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":94,"title":["An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs"],"prefix":"10.1128","volume":"87","author":[{"given":"Mojca","family":"Skoberne","sequence":"first","affiliation":[{"name":"Genocea Biosciences, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Cardin","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lee","sequence":"additional","affiliation":[{"name":"Genocea Biosciences, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Kazimirova","sequence":"additional","affiliation":[{"name":"Genocea Biosciences, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Zielinski","sequence":"additional","affiliation":[{"name":"Genocea Biosciences, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Garvie","sequence":"additional","affiliation":[{"name":"Genocea Biosciences, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Genocea Biosciences, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Larson","sequence":"additional","affiliation":[{"name":"Genocea Biosciences, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Bravo","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B.","family":"Flechtner","sequence":"additional","affiliation":[{"name":"Genocea Biosciences, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Long","sequence":"additional","affiliation":[{"name":"Genocea Biosciences, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.07.046128"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61750-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.49.1.102-108.1984"},{"key":"e_1_3_2_5_2","volume-title":"Herpes simplex virus glycoproteins","author":"Muggeridge MI","year":"1990","unstructured":"MuggeridgeMI RobertSR IsolaVJ CohenGH EisenbergRJ (ed). 1990. Herpes simplex virus glycoproteins. Elsevier, New York, NY."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.4.331"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011915"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103151"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.5.1110"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00387-X"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.1.410-418.2005"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.5.1100"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.08.025"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/315376"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.088"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/514103"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2004.05.003"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.22.11178-11184.2001"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.10.5167"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.05.011"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-82-4-845"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610847104"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/314486"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.5.2803-2810.1994"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.9.7476-7483.1998"},{"key":"e_1_3_2_26_2","volume-title":"Abstr. 37th Int. Herpesvirus Workshop","author":"Skoberne M","year":"2012","unstructured":"SkoberneM LarsonS PriceJ ZielinskiV LundbergA GierahnT CohaneK WarrenT LeoneP ScottEP GrossmanH DavisA LongD FlechtnerJB . 2012. Abstr. 37th Int. Herpesvirus Workshop, Calgary, Canada, abstr 6.05."},{"key":"e_1_3_2_27_2","first-page":"426","article-title":"Matrix M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi","volume":"5","author":"Pedersen G","year":"2011","unstructured":"PedersenG MajorD RosebyS WoodJ MadhunAS CoxRJ . 2011. Matrix M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi. Viruses 5:426\u2013437.","journal-title":"Viruses"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2007.06.005"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(91)90171-7"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.11.063"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.017"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011144"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.025"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.5.914"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.10.046"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/605645"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.11.8165-8168.1996"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/146.3.397"},{"key":"e_1_3_2_39_2","volume-title":"Abstr. 37th Int. Herpesvirus Workshop","author":"Skoberne M","year":"2012","unstructured":"SkoberneM CardinR KazimirovaA LarsonS ZielinskiV GarvieD LundbergA BernsteinDI FlechtnerJB LongD . 2012. Abstr. 37th Int. Herpesvirus Workshop, Calgary, Canada, abstr 6.09."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.23.14546-14554.2005"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.1.96-113.2003"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/505359"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04502.x"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.9.1459"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.1.83-89.2001"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.2.1146"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/591914"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2004.06.004"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92581-X"},{"key":"e_1_3_2_50_2","first-page":"161A","article-title":"Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines","volume":"11","author":"Stanberry LR","year":"2004","unstructured":"StanberryLR . 2004. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11:161A\u2013169A.","journal-title":"Herpes"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900722"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1086\/315208"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.1.7"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.5934-5944.1999"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.61.5.1532-1539.1987"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.044"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.25"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1086\/344234"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.4.1.4876"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-71-10-2391"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(98)00015-5"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1992.tb39751.x"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.4.1108"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10173"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-69-4-847"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.5.929"},{"key":"e_1_3_2_67_2","first-page":"213","article-title":"Different isotype profiles of virus-specific antibodies in acute and persistent lymphocyte choriomeningitis virus infection in mice","volume":"55","author":"Thomsen AR","year":"1985","unstructured":"ThomsenAR VolkertM MarkerO . 1985. Different isotype profiles of virus-specific antibodies in acute and persistent lymphocyte choriomeningitis virus infection in mice. Immunology 55:213\u2013223.","journal-title":"Immunology"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1086\/498247"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/157.1.156"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.07203-11"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.02745-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.02745-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T15:32:46Z","timestamp":1646494366000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.02745-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1128\/JVI.02745-12"],"URL":"https:\/\/doi.org\/10.1128\/jvi.02745-12","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"2012-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-03-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}